InvestorsHub Logo
Followers 26
Posts 3558
Boards Moderated 0
Alias Born 11/12/2018

Re: couldbebetter post# 269264

Sunday, 04/26/2020 10:10:42 AM

Sunday, April 26, 2020 10:10:42 AM

Post# of 425795
CBB, I fear that if KDPharma gets approval in Europe for FAP or FDA approval for Covid19 In the US that they will be competing for ReduceIt scripts in the same way that generics will do with the Marine indication. KD is just looking for a way to get their EPA into EU and US markets to compete with Vascepa. All IMO. I may be way off in my worry and would appreciate anyone that can tell me why I’m wrong.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News